Meeting
2015 ASCO Annual Meeting
RECORD-4: A multicenter, phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC).
Authors
Robert Motzer
Memorial Sloan Kettering Cancer Center, New York, NY
Robert Motzer , Anna Alyasova , Dingwei Ye , Andrey Karpenko , Hanzhong Li , Boris Y. Alekseev , Liping Xie , Galina Petrova Kurteva , Ruben Dario Kowalyszyn , Yeni Neron , Thomas Cosgriff , LaTonya Collins , Thomas Brechenmacher , Scott Segal , Liza M. Morgan , Lin Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01491672
Citation
J Clin Oncol 33, 2015 (suppl; abstr 4518)
DOI
10.1200/jco.2015.33.15_suppl.4518
Abstract #
4518
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Final OS analysis.
First Author: Thomas Cosgriff
Poster
2016 Genitourinary Cancers Symposium
RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
First Author: Thomas Cosgriff
Poster
2018 Genitourinary Cancers Symposium
Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
First Author: Paul L. de Souza
Poster
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
First Author: Jiahuai Tan